Telix Pharmaceuticals shares dive on US regulatory inquiry

The news: Shares in Telix Pharmaceuticals tanked 15% in early trading after the biotech company told investors on Tuesday it had received a subpoena from the US Securities and Exchange Commission (SEC).

The numbers: Telix shares were down 14.9% to $21.38 at 10:50am AEST.

The context: The SEC issued Telix with a subpoena for documents and information relating to company disclosures on its prospective cancer therapies. However, Telix said the matter is currently only a "fact-finding request".

After market close on Tuesday, the company provided unaudited revenue figures for the second quarter, showing a 63% jump year over year, and 10% rise quarter on quarter, to USD204 million ($311 million).

The biopharmaceutical group reaffirmed its revenue guidance range of between $770 million and $800 million.